• Takeda reported positive topline results from pivotal Phase 2/3 trial TAK-881-3001 in primary immunodeficiency disease, with findings already released and additional analyses slated for a future medical meeting.
• Trial met primary goal by showing investigational TAK-881 performed in line with HyQvia, supporting a potential product profile that could cut infusion volume and shorten administration time while keeping up to once-monthly dosing.
• Secondary readouts indicated comparable infection protection and a similar safety and tolerability profile versus HyQvia, with no new safety signals flagged in topline results.
• Company expects to file TAK-881 applications with US, EU, Japan regulators in fiscal year 2026, positioning program as a next-generation immunoglobulin option in a market where treatment burden remains a key differentiator.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260504944663) on May 04, 2026, and is solely responsible for the information contained therein.